Peptide Knowledge Base · Metabolic

Metformin: what it is, what the evidence says, and its real status

Not a peptide, the most-prescribed metabolic drug in the world, studied for longevity (the TAME trial).

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does Metformin work?

Reduces hepatic glucose output and improves insulin sensitivity; proposed to influence aging-related pathways including AMPK.

What it does — and what it does not do

What it does: Improves insulin sensitivity and glycemic control; studied for metabolic and longevity benefit.

What it does not do: Longevity benefit in non-diabetics is not yet proven, and it is not a peptide.

How honest is the evidence?

Evidence grade B — Good human evidence.

decades of human metabolic data; longevity case under formal trial (TAME)

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Whether it extends healthspan in metabolically healthy people is the open question TAME aims to answer.

WADA status: Not prohibited.

How it is taken

Clinician-set; oral. Educational only.

Who should not take it

Caution with significant kidney impairment; GI tolerability common early. Clinician-supervised.

Sources

Metformin metabolic literature · TAME trial (Barzilai et al.)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.